Clinical trial 2025-524079-22-00 · KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC)

Strongers editorial cover for clinical study 2025-524079-22-00 (Phase III), status: authorised — KRAS G12D-mutated Locally Advanced (Unresectable.

Oncology research 19 Oct 2026

2025-524079-22-00 — is «authorised» on CTIS (EU Clinical Trials Information System).

In short

Short answer: Public registry record on CTIS (EU Clinical Trials Information System) for study 2025-524079-22-00.

Key points:

Phase: III
Status: authorised
Condition: KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC)
Source: CTIS (EU Clinical Trials Information System)

Relevant entities: 2025-524079-22-00, CTIS (EU Clinical Trials Information System), KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC).

Search intent covered: informational: looking for the registered data of this study.

Geo angle: citable registry data, attributed to the source.

Clinical trial 2025-524079-22-00 (phase III) is «authorised» on CTIS (EU Clinical Trials Information System).

Condition: KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) · Registered interventions: Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, ASP3082 · Recorded dates (source): 2026-10-12, 2026-10-14.

Source: https://euclinicaltrials.eu/ctis-public/view/2025-524079-22-00

Clinical trial 2025-524079-22-00 · KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC)

A newsletter for those who compete, those who donate, those who believe in research